KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials

Erstveröffentlichung

2022

Authors

Kaddu-Mulindwa, Dominic

Altmann, Bettina

Robrecht, Sandra

Ziepert, Morita

Regitz, Evi

et al.

Wissenschaftlicher Artikel

Published in

The Lancet Haematology ; 9 (2022), 2. - S. E133-E142. - ISSN 2352-3026

Link to publication

https://dx.doi.org/10.1016/S2352-3026(21)00369-0

Institutions

UKU. Klinik für Innere Medizin III

Subject headings

[Free subject headings]: B-CELL LYMPHOMA | NATURAL-KILLER-CELLS | CHEMOTHERAPY PLUS RITUXIMAB | RANDOMIZED CONTROLLED-TRIAL | ELDERLY-PATIENTS | KIR | CHOP | SELF | HLA | INDIVIDUALS
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record